CMR Naviscan Corporation
Developer and distributor of dedicated breast molecular imaging systems and related clinical workflows. The company promotes radionuclide-based breast imaging (molecular breast imaging and breast PET/PEM) as adjunctive and diagnostic tools for women with dense breast tissue and other indications, cites clinical evidence and publications, and maintains a global sales and service network. Headquartered in Carlsbad, California; US FDA registered.
Industries
N/A
Products
Dual-head solid-state molecular breast imaging system (dedicated MBI)
A dedicated planar dual-head, solid-state digital imaging system for breast molecular imaging. Designed to produce high-resolution functional images for adjunct screening and diagnostic evaluation in dense breasts, with reported ~1.6 mm intrinsic spatial resolution and energy resolution under 5% FWHM.
Dual-head solid-state molecular breast imaging system (dedicated MBI)
A dedicated planar dual-head, solid-state digital imaging system for breast molecular imaging. Designed to produce high-resolution functional images for adjunct screening and diagnostic evaluation in dense breasts, with reported ~1.6 mm intrinsic spatial resolution and energy resolution under 5% FWHM.
Services
Global sales and service support network
Sales distribution and technical/service support through a global network of representatives and service centers.
Global sales and service support network
Sales distribution and technical/service support through a global network of representatives and service centers.
Expertise Areas
- Molecular breast imaging (MBI)
- Dedicated breast PET / positron-emission mammography (PEM)
- MBI-guided biopsy procedures
- Low-dose nuclear imaging protocols
Key Technologies
- Cadmium zinc telluride (CZT) solid-state detectors
- Dual-head digital gamma camera architecture
- Radionuclide photon detection and planar gamma imaging
- Positron-emission mammography (PEM) / dedicated breast PET